We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 11-20 of 2,605

Discriminating tastes: court puts long-running Robinson-Patman Act case to rest
  • Baker & Hostetler LLP
  • USA
  • September 17 2015

Described as the Rodney Dangerfield of the antitrust laws, the Robinson-Patman Actwhich prohibits anticompetitive price discriminationgets no

Kissing camels antitrust suit clears the hump of summary judgment
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • September 3 2015

In June, an antitrust suit brought by plaintiff ambulatory surgery centers ("ASCs") against a health system, health insurers, and a trade association

Antitrust implication of recent FTC patent related agreement
  • Arnall Golden Gregory LLP
  • USA
  • August 31 2015

In recent years, the Federal Trade Commission (FTC) has refocused its efforts on the interplay between the patent system and antitrust law

Third Circuit prevents physician from bringing antitrust suit against hospital that terminated his medical staff privileges
  • Barnes & Thornburg LLP
  • USA
  • August 31 2015

On Aug. 20, 2015, the United States Court of Appeals for the Third Circuit held that a physician who loses medical staff privileges at a hospital

Antitrust enforcement agencies release annual report summarizing 2014 merger enforcement activity under Hart-Scott-Rodino
  • Ober Kaler
  • USA
  • August 28 2015

The Hart-Scott-Rodino Antitrust Improvements Act (HSR) requires parties to a proposed acquisition of voting securities or assets meeting certain size

Send Lawyers, Guns and Money: providers lining up against AnthemCigna and AetnaHumana mergers
  • Baker & Hostetler LLP
  • USA
  • August 27 2015

In the wake of Anthem's proposed acquisition of Cigna and Aetna's proposed acquisition of Humana, providers are lining up to be heard. Take the

FTC issues first statement of enforcement under section 5 in 101 years
  • Epstein Becker Green
  • USA
  • August 21 2015

On August 13, 2015, the Federal Trade Commission ("FTC" or "Commission"), by a 4-1 vote, approved a bipartisan "Statement of Enforcement Principles"

Another FTC conduct case to bolster generic drug competition: pharmaceuticals charged with illegal non-compete for generic ADHD drug sales
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • August 20 2015

The Federal Trade Commission's ("FTC" or "Commission") ever-expanding list of enforcement actions to preserve competition for generic pharmaceuticals

Five lessons from 2015 healthcare deals
  • Manatt Phelps & Phillips LLP
  • USA
  • August 19 2015

In 2015, we already have seen a great deal of activity in healthcare transactions that is attracting antitrust scrutiny, with mixed results. Among

The government’s generic price-fixing investigation targets Allergan’s Actavis unit
  • Patterson Belknap Webb & Tyler LLP
  • USA
  • August 18 2015

This is our fourth post on the DOJ's expanding investigation into possible price fixing by generic drug manufacturers. (Click here, here, and here to